A novel specific antagonist anti-SIRPg antibody

Novel anti-human SIRPg antibodies with specific binding domains inhibit SIRPg-CD47 interaction and suppress IFNg secretion, addressing the need for high-yield, clinically applicable antibodies to target T cells without affecting other immune cells.

JP2024541576AInactive Publication Date: 2024-11-08OSE IMMUNOTHERAPEUTICS SA
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024531682
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-29
Filing Date
2022-11-29
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for anti-human SIRPg antibodies with high affinity for SIRPg, that do not cross-react with SIRPa, and have a high production yield suitable for clinical use, to specifically target T cells without affecting other immune cells.

Method used

Development of novel anti-human SIRPg antibodies with specific binding domains (VLCDR1, VLCDR2, VLCDR3, VHCDR1, VHCDR2, VHCDR3) that inhibit the SIRPg-CD47 interaction, while not affecting SIRPa-CD47, and are produced in high yields, achieving 100-10,000-fold higher than previous antibodies.

Benefits of technology

The antibodies effectively inhibit SIRPg-CD47 interaction, suppress interferon gamma (IFNg) secretion, and are suitable for clinical use due to their high production yield and specificity, providing a therapeutic approach for diseases involving T cell proliferation and activation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541576000008
    Figure 2024541576000008
  • Figure 2024541576000009
    Figure 2024541576000009
  • Figure 2024541576000010
    Figure 2024541576000010
Patent Text Reader

Abstract

The present invention relates to the field of immunotherapy. The present invention relates to novel specific anti-SIRPg antibodies and their therapeutic uses.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of immunotherapy. The present invention relates to novel specific antagonist anti-SIRPg antibodies and their therapeutic uses. [Background technology]

[0002] Signal transduction regulatory proteins (SIRPs) constitute a family of transmembrane glycoproteins that are widely expressed in the immune and central nervous systems and transduce a variety of signals.

[0003] The prototypic member of the SIRP family is SIRP-alpha (also called SIRPa, SIRPα, CD172a or SHPS-1). The gene encoding human SIRPa is a polymorphic gene, and several variants have been reported in the human population. The most common protein variants are SIRPa v1 (accession numbers NP_542970 and P78324) and SIRPa v2 (accession number CAA71403).

[0004] SIRPa is expressed on monocytes, most subpopulations of tissue macrophages, granulocytes, a subset of dendritic cells in lymphoid tissues, some bone marrow progenitor cells, and at various levels of neurons, with particular expression in synaptic-rich brain regions such as the granular layer of the cerebellum and the hippocampus. SIRPa is an inhibitory receptor that binds CD47 and regulates macrophage and dendritic cell function and signaling pathways induced by growth factors and cell adhesion.

[0005] Another member of the SIRP family, SIRP-beta (also called SIRPb, SIRPβ, CD172b or SIRP beta-1 - Accession number NM_001083910 or Accession number Q5TFQ8), has also been identified. Unlike other members of the SIRP family, SIRPb does not appear to bind to CD47 and its ligand remains unknown.

[0006] A third member of the SIRP family, SIRP-gamma (also called SIRPg, SIRPγ, CD172g or SIRP beta-2 - Accession No. NM_018556 or Accession No. Q9P1W8), was later identified. SIRPg is variably expressed in many human tissues, but is specifically expressed on the surface of T cells, where it binds to CD47 (Piccio et al., Blood, 105:6, 2005).

[0007] Only a few anti-SIRPg antibodies have been used in the past. The anti-SIRPa antibody, Kwar23 antibody, has been shown to also bind to SIRPg (see WO2017 / 178653). Brooke et al. have disclosed the production of mouse antibodies OX116, 117, 118 and 119. Among these antibodies, mAb OX119 was selected as being more specific. However, some peripheral blood myeloid cells were stained with the OX119 antibody, which was thought to be the result of cross-reactivity.

[0008] Targeting specific epitopes on SIRPg with antagonistic monoclonal antibodies that do not affect the SIRPa / CD47 interaction, in contrast to the prior art antibodies, could be a more specific strategy to target only T cells while avoiding effects on other immune cells, thus avoiding side effects in therapeutic use.

[0009] Stefanidakis M. et al. used the anti-SIRPg LSB2.20 antibody to show that CD47 is concentrated at the intercellular junctions of endothelial cells and that CD47 interacting with human T cell SIRPg plays an important role in T cell migration in vitro (Stefanidakis M. et al, Blood, 2008, 112 (4): 1280-1289). The anti-SIRPg LSB2.20 antibody used in this study is disclosed as a specific antibody, but the cross-reactivity and antagonistic activity of this anti-SIRPg with SIRPa are not precisely discussed in the text. The applicant previously developed anti-human SIRPg antibodies A1, A5, and A8 that selectively bind to SIRPg (WO2020 / 039049). However, it has been found that the production yield of these antibodies is not sufficient for clinical use. [Prior art documents] [Patent documents]

[0010] [Patent Document 1] WO2017 / 178653 [Patent Document 2] WO2020 / 039049 [Non-patent literature]

[0011] [Non-Patent Document 1] Piccio et al., Blood, 105:6, 2005 [Non-Patent Document 2] Stefanidakis M. et al, Blood, 2008, 112 (4): 1280-1289 Summary of the Invention [Problem to be solved by the invention]

[0012] Thus, there remains a need to develop improved anti-human SIRPg antibodies that have high affinity for SIRPg, are antagonists of the SIRPg-CD47 interaction but are not antagonists of the SIRPa-CD47 interaction, and in particular do not cross-react with SIRPa, that can be produced in high production yields and therefore are suitable for clinical use. [Means for solving the problem]

[0013] The present inventors have developed novel anti-human SIRPg antibodies that recognize and specifically bind to SIRPg antigens with high affinity. These antibodies are potent inhibitors of the interaction between human SIRPg and human CD47, but are not antagonists of human SIRPa-CD47 interaction (they do not specifically bind to human SIRPa), and have a strong effect in inhibiting the secretion of interferon gamma (IFNg). Furthermore, the production yield of these antibodies was found to be 100- to 10,000-fold higher than some prior art antibodies, and therefore suitable for clinical use.

[0014] The present disclosure relates to anti-SIRPg antibodies or antigen-binding fragments thereof that specifically bind to SIRPg, particularly human SIRPg, comprising: a) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 23, a VLCDR2 of SEQ ID NO: 24, and a VLCDR3 of SEQ ID NO: 25, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 26, a VHCDR2 of SEQ ID NO: 27, and a VHCDR3 of SEQ ID NO: 28; b) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 29, a VLCDR2 of SEQ ID NO: 30, and a VLCDR3 of SEQ ID NO: 31, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 32, a VHCDR2 of SEQ ID NO: 33, and a VHCDR3 of SEQ ID NO: 34; c) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 35, a VLCDR2 of SEQ ID NO: 36, and a VLCDR3 of SEQ ID NO: 37, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 38, a VHCDR2 of SEQ ID NO: 39, and a VHCDR3 of SEQ ID NO: 40; d) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 41, a VLCDR2 of SEQ ID NO: 42, and a VLCDR3 of SEQ ID NO: 43, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 44, a VHCDR2 of SEQ ID NO: 45, and a VHCDR3 of SEQ ID NO: 46, or e) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 47, a VLCDR2 of SEQ ID NO: 48, and a VLCDR3 of SEQ ID NO: 49, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 50, a VHCDR2 of SEQ ID NO: 51, and a VHCDR3 of SEQ ID NO: 52. Includes.

[0015] In certain embodiments, the antibody or antigen-binding fragment thereof specifically binds to a polypeptide comprising or consisting of SEQ ID NO:1 or 2, in particular consisting of SEQ ID NO:1 or 2.

[0016] According to the present disclosure, the anti-SIRPg antibody or antigen-binding fragment thereof inhibits the binding of human CD47 to human SIRPg as described above. In a more specific embodiment, the anti-SIRPg antibody or antigen-binding fragment thereof does not inhibit the binding of human SIRPa to human CD47 as described above, and preferably does not bind to human SIRPa.

[0017] In a preferred embodiment, the anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure inhibits IFNg secretion by T cells, preferably chronically activated T cells, compared to a negative control, in particular the inhibition of IFNg secretion is 20% or more, preferably 30% or more, more preferably 40% or more.

[0018] In certain embodiments, the antibody or antigen-binding fragment thereof according to the present disclosure is a humanized monoclonal antibody or antigen-binding fragment thereof and comprises a human IgG4 heavy chain constant region, preferably comprising or consisting of SEQ ID NO: 103, and / or comprises a human Igκ light chain constant region, preferably comprising or consisting of SEQ ID NO: 104.

[0019] In a more preferred embodiment, the anti-SIRPg antibody or antigen-binding fragment thereof has the following: - a light chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 3 and a heavy chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 4; - a light chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO:5 and a heavy chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO:6; - a light chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 7 and a heavy chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 8; - a light chain variable domain comprising or consisting of the amino acid sequence of SEQ ID NO: 9 and a heavy chain variable domain comprising or consisting of the amino acid sequence of SEQ ID NO: 10; or - a light chain variable domain comprising or consisting solely of the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable domain comprising or consisting solely of the amino acid sequence of SEQ ID NO: 12 Includes.

[0020] In another aspect, the present disclosure relates to an isolated nucleic acid molecule or a combination of isolated nucleic acid molecules encoding the antibody or antigen-binding fragment thereof described above.

[0021] The present disclosure also relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, or the isolated nucleic acid molecule or a combination of the isolated nucleic acid molecules described above, and a pharmaceutical vehicle.

[0022] Such products are particularly suitable for use in the prevention and / or treatment of a number of diseases, in particular diseases in which T cells are involved (diseases in which T cells have a deleterious effect), in particular for use in modulating T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells, in particular where affecting T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells may improve the outcome of the disease.

[0023] Therefore, the present disclosure also relates to the anti-SIRPg antibody or antigen-binding fragment thereof, the isolated nucleic acid molecule, the combination of the isolated nucleic acid molecule or the pharmaceutical composition described above for use in the treatment of a disease in which T cells have a detrimental effect, in particular a disease in which T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells has a detrimental effect, preferably the disease is selected from the group consisting of autoimmune diseases, inflammatory diseases, immunometabolic diseases, cardiovascular diseases caused by systemic inflammation, and transplant dysfunction or rejection. In a preferred embodiment, the transplant dysfunction or rejection is graft-versus-host disease. In a more preferred embodiment, the inflammatory disease is a chronic inflammatory disease such as inflammatory bowel disease, including Crohn's disease or ulcer disease. In another particular embodiment, the disease is a chronic neuroinflammatory disease.

[0024] Finally, the present disclosure relates to a combination product comprising the above-mentioned anti-SIRPg antibody, antigen-binding fragment thereof, isolated nucleic acid molecule, combination of isolated nucleic acid molecules, or pharmaceutical composition; wherein the second therapeutic agent is selected from the group consisting of immunotherapeutic agents, immunosuppressants, antibiotics, probiotics, and mixtures thereof, preferably, said immunosuppressant is selected from the group consisting of cyclosporine A, tacrolimus, mycophenolate mofetil, rapamycin, steroids, anti-TNF agents, anti-IL-23 agents. In certain embodiments, the present disclosure relates to a combination product for simultaneous, separate, or sequential use as a pharmaceutical. [Brief description of the drawings]

[0025] [Figure 1] Figure 1: Binding ELISA assay for immobilized protein SIRPg-His at 1 μg / ml. A) Binding analysis of antibodies 13F7, 11B5 and 26F10 with A1, A5 and Kwar23 antibodies of the prior art, and B) 11B5, 2H9 and 3H8 with Kwar23 antibody of the prior art. Visualization was performed with donkey anti-human antibody and visualized by colorimetry at 450 nm with TMB substrate. Isotype IgG4m was used as negative control. [Diagram 2] Figure 2: SIRPg binding analysis of antibodies on Jurkat cells by cytofluorometry. Cytofluorometric assessment of the binding of 13F7, 26F10, 2H9, and 3H8 and prior art LSB2.20 and OX119 antibodies on human Jurkat cells (previously stained with human Fc receptor binding inhibitor antibodies). A) Percentage of positive Jurkat cells, B) Mean fluorescence intensity (MFI). [Diagram 3] Figure 3: SIRPa binding ELISA assay. Binding analysis of antibodies 13F7, 11B5, 2H9, 3H8, and 26F10 as well as prior art anti-SIRPa and Kwar23 antibodies. Visualization was performed with donkey anti-human antibody and visualized by colorimetric measurement at 450 nm with TMB substrate. Isotype IgG4 m was used as negative control. [Figure 4] Figure 4: CD47 and antibody competition for SIRPa. Evaluation of (A) LSB2.20 and OX119 antibodies and (B) 13F7, 11B5, 26F10, 2H9, and 3H8 antibodies as well as the prior art LSB2.20 and OX119 antibodies against immobilized SIRPa-His by ELISA was performed at different concentrations, incubated with a constant concentration of biotinylated CD47-Fc (3 μg / ml). Visualization was performed using streptavidin peroxidase to detect CD47 molecules and colorimetric measurement at 450 nm with TMB substrate. Isotypes IgG1m and IgG4m were used as negative controls. [Diagram 5]Figure 5: Anti-SIRPg antagonist activity by competitive ELISA assay with CD47. (A) Binding analysis of anti-SIRPg antibodies 13F7, 26F10, 2H9, and 3H8, and (B) 11B5, 13F7, 26F10, and 3H8 antibodies. ELISA was performed by incubating different concentrations of antibodies with a constant concentration of biotinylated CD47-Fc (3 μg / ml). Visualization was performed using streptavidin peroxidase to detect CD47 molecules and colorimetrically at 450 nm or 450-630 nm with TMB substrate. [Figure 6] Figure 6: Antagonist activity in biological assays. PBMCs were stimulated in triplicate in complete medium in plates coated with 3 μg / ml anti-CD3 (OKT3) and 3 μg / ml soluble anti-CD28.2. For functional assays, exhausted or unstimulated PBMCs were activated in plates coated with 0.5 μg / ml anti-CD3 (OKT3) and 10 μg / ml human CD47Fc recombinant protein (#12283-H02H, SinoBiological). The antibodies were then incubated on plates with exhausted or unstimulated PBMCs for 2 days to measure IFNg secretion (#555142, BDBiosciences) and proliferation by AlamarBlue detection at 530 nm (#DAL1100, Invitrogen) and for 5 days at 37°C, 5% CO2. (A) Percentage of IFNg secretion after treatment of PBMCs with 1 μg / mL of 3H8 antibody and prior art Kwar23, OX119, and LSB2.20 antibodies for 48 hours; (B) Percentage of IFNg secretion after treatment of PBMCs with 10 μg / mL of 11B5, 26F10, 13F7, 2H9 antibodies and prior art Kwar23 antibody for 48 hours. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0026] definition

[0027] As used herein, the term "SIRPg" has its general meaning in the art and refers to a mammalian SIRPg protein, preferably human SIRPg. SIRPg is a receptor-type transmembrane glycoprotein known to be involved in the negative regulation of receptor tyrosine kinase-coupled signal transduction processes and is encoded by the SIRPg gene (Gene ID: 55423, updated July 8, 2021). The reference sequence of the human SIRPg protein corresponds to the sequence linked to UniProtKB accession number Q9P1W8, updated June 2, 2021.

[0028] As used herein, the term "CD47" refers to mammalian CD47 protein, preferably human CD47, a membrane protein involved in the increase in intracellular calcium concentration that occurs upon cell adhesion to the extracellular matrix. The encoded protein is also a receptor for the C-terminal cell-binding domain of thrombospondin and may play a role in membrane trafficking and signal transduction. The CD47 gene (Gene ID: 961, updated November 8, 2021) encodes two isoforms: CD47 isoform X2 (NCBI Reference Sequence: XP_005247966.1, updated May 16, 2021) and CD47 isoform X3 (NCBI Reference Sequence: XP_016863025.1, updated May 16, 2021).

[0029] As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that have an antigen-binding site that specifically binds to an antigen. Thus, the term antibody encompasses whole antibody molecules, such as four-chain antibodies consisting of two heavy chains and two light chains, such as polyclonal antibodies, monoclonal antibodies, or recombinant antibodies.

[0030] In natural antibodies from rodents and primates, two heavy chains are linked to each other by disulfide bonds, and each heavy chain is linked to a light chain by a disulfide bond. There are two types of light chains: lambda (λ) and kappa (κ). There are five main heavy chain classes (or isotypes) that determine the functional activity of the antibody molecule: IgM, IgD, IgG, IgA, and IgE. Each chain contains different sequence domains. In a typical IgG antibody, the light chain contains two domains: a variable domain (VL) and a constant domain (CL). The heavy chain contains four domains, a variable domain (VH) and three constant domains (CH1, CH2, and CH3, collectively referred to as CH). Together, the variable region of the light chain (VL) and the variable region of the heavy chain (VH) determine the binding recognition and specificity to the antigen. The light chain constant domain (CL) and the heavy chain constant domain (CH) confer important biological properties such as antibody chain assembly, secretion, placental transport, complement fixation, and Fc receptor (FcR) binding.

[0031] Fv fragment is the N-terminal part of the Fab fragment of an immunoglobulin and consists of one light chain and one heavy chain variable part. The specificity of an antibody is provided by the structural complementarity between the antibody binding site and the antigenic determinant. The antibody binding site is mainly composed of residues from the hypervariable regions or complementarity determining regions (CDRs). Sometimes, residues from non-hypervariable regions or framework regions (FRs) may also participate in the antibody binding site or affect the structure of the entire domain, which may affect the binding site.

[0032] Complementarity Determining Regions (CDRs) refer to amino acid sequences that determine the binding affinity and specificity of the natural Fv region of a natural immunoglobulin binding site. The light and heavy chains of an immunoglobulin each have three CDRs, which are called L-CDR1, L-CDR2, L-CDR3 and H-CDR1, H-CDR2, H-CDR3, respectively. Thus, an antigen-binding site usually contains six CDRs, including those set from the variable (V) regions of the heavy and light chains.

[0033] Framework region (FR) refers to the amino acid sequence between the CDRs. Thus, the light and heavy chain variable regions usually contain four framework regions and three CDRs with the following sequence: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0034] The skilled artisan can determine the location of the various regions / domains of an antibody by reference to standard definitions given in the art, including reference numbering systems, reference to the KABAT numbering system, or application of the IMGT "collier de perle" algorithm. In this regard, it should be noted that when defining the sequences of the invention, the delimitation of the regions / domains may differ depending on the system of reference. Thus, the regions / domains defined in the present invention encompass sequences that exhibit about ±10% variation in length or position of the relevant sequence within the full-length sequence of the variable domain of an antibody.

[0035] The predicted CDRs (according to the KABAT numbering system) of anti-SIRPg antibodies according to the present disclosure, such as 2H9, 3H8, 26F10, 13F7, and 11B5, are set forth in Table 3 below.

[0036] As used herein, the term "monoclonal antibody" refers to a preparation of antibody molecules with a single specificity. A monoclonal antibody refers to a single binding specificity and affinity for a particular epitope. Thus, the term "human monoclonal antibody" refers to an antibody exhibiting a single binding specificity having variable and constant regions derived from or based on human germline immunoglobulin sequences or derived from entirely synthetic sequences. The method of preparation of a monoclonal antibody does not relate to the binding specificity. In one embodiment, the antibody of the present disclosure is a monoclonal antibody.

[0037] As used herein, the term "recombinant antibody" refers to an antibody that is produced, expressed, generated or isolated by recombinant means, e.g., an antibody expressed using a recombinant expression vector introduced into a host cell; an antibody isolated from a recombinant combinatorial antibody library; an antibody isolated from an animal (e.g., a mouse) that has been genetically modified with human immunoglobulin genes; or an antibody produced, expressed, generated or isolated in any other manner in which a particular immunoglobulin gene sequence (e.g., a human immunoglobulin gene sequence) is assembled with other DNA sequences. Recombinant antibodies include, for example, chimeric and humanized antibodies.

[0038] The term "antigen-binding fragment" of an antibody (or simply "antibody fragment"), as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to an antigen (e.g., SIRPg). It has been shown that the antigen-binding function of an antibody can be exerted by fragments of a full-length antibody.

[0039] Examples of binding fragments encompassed by the term "antigen-binding fragment" of an antibody include a Fab fragment, which is a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; a F(ab)2 fragment, which is a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region; an Fd fragment consisting of the VH and CH1 domains; an Fv fragment consisting of the VL and VH domains of a single arm of an antibody; a dAb fragment consisting of the VH domain (Ward et al., 1989 Nature 341:544-546), or any fusion protein comprising such an antigen-binding fragment. Furthermore, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, they can be linked by a synthetic linker that allows them to be made using recombinant methods as a single-chain protein in which the VL and VH regions pair to form a monovalent molecule (known as single-chain Fv (scFv); see, for example, Bird et al., 1988 Science 242:423-426; and Huston et al., 1988 Proc.Natl. Acad. Sci. 85:5879-5883). Such single-chain antibodies are also intended to be encompassed by the term "antigen-binding fragment" of an antibody. These antibody fragments are obtained using conventional techniques known to those skilled in the art, and the fragments are screened for utility in the same manner as intact antibodies.

[0040] As used herein, a "chimeric antibody" refers to an antibody in which variable domain sequences derived from the germline of a mammalian species, such as mouse, are joined to constant domain sequences derived from the germline of another mammalian species, such as human. In one embodiment, an antibody of the present disclosure is a chimeric antibody.

[0041] In one embodiment, the antibody of the present disclosure is a humanized antibody. As used herein, "humanized antibody" refers to an antibody in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.

[0042] As used herein, a "modified antibody" corresponds to a molecule comprising an antibody or an antigen-binding fragment thereof, said antibody or functional fragment thereof being linked to a functionally distinct molecule. The modified antibodies of the present invention may be fusion chimeric proteins or complexes, resulting from any suitable form of conjugation, including covalent bonding, grafting, chemical bonding with chemical or biological groups, or chemical bonding with molecules such as PEG polymers or other protecting groups or molecules suitable for protection against protease cleavage in vivo, to improve the stability and / or half-life of the antibody or functional fragment.

[0043] By similar techniques, in particular chemical coupling or grafting, modified antibodies can be prepared with biologically active molecules, said active molecules being for example selected from toxins, in particular Pseudomonas exotoxin A, the A chain of the plant toxin ricin or saporin toxin, in particular therapeutic active principles, vectors (including in particular protein vectors) suitable for targeting antibodies or functional fragments to specific cells or tissues of the human body, or, in particular if fragments of antibodies are used, can be conjugated to labels or linkers.

[0044] PEGylation of antibodies or functional fragments thereof is an interesting embodiment, especially in therapeutic applications, because it improves the conditions for delivery of active substances to the host. PEGylation can be site-specific to prevent interference with the recognition site of the antibody or functional fragment, and can be performed with high molecular weight PEG. PEGylation can be performed via a free cysteine ​​residue present in the sequence of the antibody or functional fragment, or via a free cysteine ​​residue added in the amino acid sequence of the antibody or functional fragment. In an embodiment, the anti-SIRPg antibody or antigen-binding fragment thereof of the present disclosure is modified, and in certain cases is a modified antibody.

[0045] Anti-SIRPg antibody or antigen-binding fragment thereof

[0046] The antibody or antigen-binding fragment thereof of the present disclosure has the property of specifically binding to SIRPg, particularly human SIRPg, with high affinity. As exemplified in the examples of the present disclosure, the antibody or antigen-binding fragment thereof inhibits the interaction between human CD47 and human SIRPg, and has a strong effect on suppressing interferon gamma (IFNg) secretion. These antibodies or antigen-binding fragments thereof do not inhibit the interaction between human CD47 and human SIRPa, and do not specifically bind to SIRPa, particularly human SIRPa, preferably human SIRPa.

[0047] According to the present disclosure, an antibody or antigen-binding fragment thereof according to the present disclosure specifically binds to a SIRPg antigen.

[0048] The expressions "antibody that recognizes an antigen" and "antibody that binds to an antigen" are used interchangeably herein. As used herein, the term "recognize" refers to the ability of an antibody or an antigen-binding fragment thereof to detectably bind to an epitope presented on an antigen, i.e., an SIRPg antibody, in particular an epitope of human SIRPg that consists of or is located in the extracellular loop of the receptor, more specifically the polypeptide of SEQ ID NO: 1 or 2, preferably SEQ ID NO: 2. Typically, binding affinity can be measured by methods known in the art, such as, but not limited to, Biacore analysis, Blitz analysis, ELISA assay or Scatchard plot.

[0049] In certain embodiments, an antibody or antigen-binding fragment according to the present disclosure specifically binds to human SIRPg antigen with an EC50 of 100 ng / ml or less, preferably 0.1 to 100 ng / ml, more particularly 5 ng / ml to 50 ng / ml, as may be determined by ELISA binding assay. In another embodiment, it binds to human SIRPg antigen with an EC50 of 50 ng / ml or less, 40 ng / ml or less, 30 ng / ml or less, 20 ng / ml or less, as may be determined by ELISA binding assay or the methods disclosed in the Examples of the present invention (see Method 1.4 detailed in the Examples of the present application and the results detailed in Figure 1).

[0050] In certain embodiments, an antibody or antigen-binding fragment according to the present disclosure binds to human SIRPg antigen with an EC50 of 3.5 μg / ml or less, particularly 3 μg / ml or less, more particularly 2.5 μg / ml or less, 2 μg / ml or less, 1.5 μg / ml or less, 1 μg / ml or less, 0.5 μg / ml or less, as may be determined by a cytofluorimetric binding assay or the methods disclosed in the Examples of the present invention (see Method 1.5 detailed in the Examples of the present application and the results detailed in Table 5 and Figure 2).

[0051] As used herein, the term "EC50" refers to a measure of the effectiveness of an antibody or antigen-binding fragment thereof (e.g., an anti-SIRPg antibody or antigen-binding fragment thereof) to elicit 50% of a biological or biochemical function (e.g., a function or activity of SIRPg). For example, EC50 indicates the amount of an anti-SIRPg antibody or antigen-binding fragment thereof required to elicit half the activity of SIRPg. That is, it is half (50%) of the maximum effective concentration (EC) of the anti-SIRPg antibody or antigen-binding fragment thereof (50% EC or EC50). EC50 represents the concentration of an agent required to show 50% efficacy in vitro. EC50 can be determined by techniques known in the art, such as, for example, constructing a dose-response curve and examining the effect of different concentrations of an anti-SIRPg antibody or antigen-binding fragment thereof on SIRPg activity, such as anti-SIRPg binding. In particular, EC50 represents the concentration of the indicated antibody or antigen-binding fragment thereof to reach 50% of binding in the ELISA binding assay or the cytofluorimetric binding assay described in methods 1.3 and 1.5 detailed in the Examples.

[0052] The present disclosure also relates to an antibody or antigen-binding fragment thereof that specifically binds to human SIRPg with an affinity constant, KD, of greater than 10E-8M, as can be determined by biosensor analysis.

[0053] According to one embodiment of the disclosure, the antibody or antigen-binding fragment thereof specifically binds to SIRPg, e.g. does not cross-react with (bind to) SIRPa and / or SIRPb, particularly SIRPa, more particularly human SIRPa.

[0054] "Selective binding" or "specific binding" typically means that an antibody or antigen-binding fragment thereof binds more strongly to a target, such as an epitope, and is specific compared to binding to other targets. An antibody or antigen-binding fragment binds more strongly to a first target compared to a second target if its affinity to the first target is higher than its affinity to the second target. Typically, an antibody or antigen-binding fragment thereof binds more strongly to a first target compared to a second target if it binds to the first target with an EC50 lower than the aforementioned EC50 for the second target. Most specifically, the agent does not bind to the second target to any significant extent at all.

[0055] The selective binding of the antibodies or antigen-binding fragments thereof disclosed herein can be tested using a cross-reactivity assay for other SIRP members, such as SIRPa and / or SIRPb, preferably SIRPa compared to the intended target protein (SIRPg). If no such cross-reactivity is detected, while at the same antibody dilution it gives a strong signal for the intended target, the antibody or antigen-binding fragment thereof is generally considered to be selective (see results detailed in the corresponding examples in Table 6 and Figure 3).

[0056] An antibody or antigen-binding fragment thereof that "does not cross-react with an antigen" or "does not bind to an antigen" is intended to refer to an antibody or antigen-binding fragment thereof that binds to its antigen, such as SIRPa and / or SIRPb, preferably SIRPa, with an EC50 of more than 1000 ng / ml, in particular more than 10000 ng / ml, as can be determined in an ELISA binding assay, more particularly an EC50 that cannot be determined in a standard binding assay (such as an ELISA binding assay). In particular, the EC50 represents the concentration of the indicated antibody or antigen-binding fragment thereof to reach 50% of binding in the ELISA binding assay described in methods 1.3 (see results in Figure 3) and 1.4 detailed in the Examples. In a preferred embodiment, such an antibody or antigen-binding fragment thereof that does not cross-react with or does not bind to an antigen shows essentially undetectable binding to said antigen, such as SIRPa and / or SIRPb, preferably SIRPa, in a standard binding assay (which can be determined by an ELISA binding assay or a cytofluorimetric binding assay).

[0057] In another specific embodiment, an antibody or antigen-binding fragment thereof according to the present disclosure does not inhibit SIRPa-CD47 interaction, preferably human SIRPa-human CD47 interaction. In a specific embodiment, such an antibody or antigen-binding fragment thereof that does not cross-react with the antigen exhibits essentially undetectable inhibition or prevention of SIRPa binding to CD47, as assessed, for example, by a competitive ELISA assay, as described in the Examples of the present disclosure (see Method 1.6 and results in Figure 4, detailed in the Examples).

[0058] In some embodiments, an anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure allows less than 20% inhibition of physical binding of CD47 to SIRPa, preferably less than 10%, and more preferably less than 5%, at concentrations greater than 400 ng / ml, more particularly greater than 800 ng / ml, and most particularly greater than 1000 ng / ml, as can be determined by competitive ELISA assay.

[0059] In a more particular embodiment, the specific anti-SIRPg antibody or antigen-binding fragment thereof according to the invention has an EC50 value for SIRPg binding lower than 100 ng / ml, more particularly lower than 50 ng / ml, such that the EC50 value for SIRPa and / or SIRPb binding, preferably SIRPa binding, can be determined by an ELISA binding assay, higher than 1000 ng / ml, particularly higher than 10000 ng / ml, such that the EC50 value for SIRPa and / or SIRPb, preferably SIRPa binding, cannot be determined by a standard binding assay (e.g. ELISA binding assay or cytofluorometric binding assay).

[0060] The antibody or antigen-binding fragment thereof having specific binding to SIRPg according to the present disclosure is also typically further characterized by its ability to inhibit or prevent SIRPg-CD47 interaction, preferably human SIRPg-human CD47 interaction. The antagonistic properties of the antibody or antigen-binding fragment thereof, in other words its ability to inhibit or prevent the binding of SIRPg to CD47, can be assessed, for example, by a competitive ELISA assay, as described in the Examples of the present disclosure (see method 1.6 and results in Figure 5 detailed in the Examples).

[0061] In some embodiments, an anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure allows inhibition of physical binding between CD47 and SIRPg by more than 60%, more preferably more than 70%, more preferably more than 80%, and most preferably more than 90% at concentrations below 1000 ng / ml, more particularly below 800 ng / ml, and most particularly below 400 ng / ml. The antagonist effect can be determined using method 1.6 as illustrated in the examples of the present application.

[0062] The antibodies or antigen-binding fragments thereof according to the present disclosure are further characterized as inhibiting T cell proliferation, T cell activation, tissue infiltration and / or migration of T cells compared to a negative control, and preferably inhibiting T cell proliferation and / or T cell activation.

[0063] Antibodies or antigen-binding fragments thereof of the present disclosure having such advantageous properties can be screened among anti-SIRPg antibodies, for example, using the following assay.

[0064] T cell proliferation can be measured by H3-thymidine incorporation. In particular, an antibody or antigen-binding fragment thereof is considered to inhibit T cell proliferation if T cell proliferation is reduced by 20% or more compared to a negative control.

[0065] The activation of T cells can be assessed by analyzing the expression of CD25 and / or CD69, for example by flow cytometry, Western blot, ELISA, etc., and / or by analyzing the secretion of IFNg and / or IL2, in comparison with a control known not to activate T cells. In particular, the antibody or antigen-binding fragment according to the present disclosure inhibits the secretion of interferon gamma (IFNg) cytokines by T cells and / or natural killer cells, in particular T cells, more particularly chronically activated T cells, in particular reducing or inhibiting IFNg secretion by T cells in comparison with a negative control, in particular reducing or inhibiting IFNg secretion by more than 20%, preferably more than 30%, more preferably more than 40%, even more preferably more than 50%, even more preferably more than 60%. The negative control can be a medium without the antibody or a medium containing an antibody known not to activate T cells. The chronically activated T cells are advantageously T cells stimulated with anti-CD3 (OKT3) and anti-CD28 antibodies, as described in method 1.7 of the Examples.

[0066] The secretion level (concentration) of IFNg can be assessed by any method known to the skilled artisan, for example by measuring the level of IFNg secreted by T cells (e.g., chronically activated T cells) by immunoassay, in particular ELISA, as described in the examples of the present disclosure (see method 1.7 detailed in the examples and Figure 6 of the present application).

[0067] Tissue infiltration and migration of T cells can be assessed by counting the number of T cells in a specific location in the body (e.g., tissue, organ, body fluid, gland) over time in the presence of an anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure compared to a negative control. T cell tissue infiltration is considered positive if the number of T cells increases over time. T cell migration is considered positive if the number of T cells changes over time. T cells can be counted according to known methods, such as, but not limited to, using specific T cell markers.

[0068] According to one embodiment, the anti-human SIRPg antibodies or antigen-binding fragments thereof according to the present disclosure include selected recombinant anti-SIRPg antibodies 2H9, 3H8, 26F10, 13F7, and 11B5, which are structurally characterized by the amino acid sequences of the heavy chain variable domain and the light chain variable domain as set forth in Table 1 below.

[0069] [Table 1] Table 1: Amino acid sequences of the variable heavy and variable light chains of 2H9, 3H8, 26F10, 13F7, and 11B5.

[0070] The present disclosure relates to an anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure, comprising a light chain variable domain comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, and SEQ ID NO:11, and / or comprising a heavy chain variable domain comprising or consisting of an amino acid sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, and SEQ ID NO:12.

[0071] In certain embodiments, an antibody or antigen-binding fragment thereof according to the present disclosure comprises: a) a light chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO: 3, and a heavy chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO: 4; b) a light chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO:5 and a heavy chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO:6; c) a light chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO: 7 and a heavy chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO: 8; d) a light chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 9 and a heavy chain variable region comprising or consisting of the amino acid sequence of SEQ ID NO: 10; or e) a light chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region comprising or consisting solely of the amino acid sequence of SEQ ID NO: 12 Includes.

[0072] In certain embodiments of the disclosure, the variable region of such antibodies may be associated with an antibody constant region such as IgA, IgM, IgE, IgD, or IgG, e.g., IGg1, IgG2, IgG3, IgG4. The variable region of said antibodies is associated with a human IgG4 heavy chain constant region, preferably comprising or consisting of SEQ ID NO: 103, and / or a human kappa light chain constant region, preferably comprising or consisting of SEQ ID NO: 104.

[0073] The full-length light and heavy chain amino acid sequences of the selected recombinant anti-SIRPg antibodies 2H9, 3H8, 26F10, 13F7, and 11B5 are shown in Table 2.

[0074] [Table 2-1] [Table 2-2] Table 2: Full length heavy and light chain amino acid sequences of recombinant anti-SIRPg antibodies 2H9, 3H8, 26F10, 13F7, and 11B5. The amino acid sequences of the constant isotype regions, IgG4m (S288P): SEQ ID NO: 103 and CL kappa: SEQ ID NO: 104, are shown in bold.

[0075] Thus, in certain embodiments, an antibody or antigen-binding fragment thereof according to the present disclosure comprises a light chain amino acid sequence selected from the group consisting of SEQ ID NOs: 13, 15, 17, 19, and 21, and / or a heavy chain amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 16, 18, 20, and 22.

[0076] In a more specific embodiment, the antibody or antigen-binding fragment thereof comprises: a) a light chain amino acid sequence of SEQ ID NO: 13 and a heavy chain amino acid sequence of SEQ ID NO: 14; b) a light chain amino acid sequence of SEQ ID NO: 15 and a heavy chain amino acid sequence of SEQ ID NO: 16; c) a light chain amino acid sequence of SEQ ID NO: 17 and a heavy chain amino acid sequence of SEQ ID NO: 18; d) a light chain amino acid sequence of SEQ ID NO: 19 and a heavy chain amino acid sequence of SEQ ID NO: 20; e) the light chain amino acid sequence of SEQ ID NO: 21 and the heavy chain amino acid sequence of SEQ ID NO: 22 Includes.

[0077] Anti-SIRPg antibodies or antigen-binding fragments thereof having an amino acid sequence having at least 90%, such as at least 95%, 96%, 97%, 98% or 99% identity to any one of the above defined amino acid sequences are also part of the present disclosure, typically the anti-SIRPg antibody has at least the same or higher antagonist activity against the above-mentioned SIRPg-CD47 interaction (and / or SIRPg binding affinity) and at least the same or lower non-antagonistic activity against the SIRPa-CD47 interaction compared to said anti-SIRPg antibody consisting of a VH and a VL, in particular said anti-SIRPg antibody consisting of a heavy chain and a light chain of any one of the 2H9, 3H8, 26F10, 13F7 and 11B5 antibodies.

[0078] As used herein, the percentage of identity between two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity = number of identical positions / total number of positions x 100), taking into account the number of gaps and the length of each gap that need to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of the percentage of identity between two sequences can be accomplished using a mathematical algorithm, as described below.

[0079] The percentage of identity between two amino acid or nucleotide sequences can be determined using the algorithm of E. Meyers and W. Miller (Comput. Appl. Biosci., 4:11-17, 1988) as incorporated into the ALIGN program (version 2), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. Alternatively, the percentage of identity between two amino acid or nucleotide sequences can be determined using the algorithm of Needleman and Wunsch (J. Mol., Biol. 48:444-453, 1970) as incorporated into the GAP program of the GCG software package (available at http: / / www.gcg.com), using either a Blossom 62 matrix or a PAM250 matrix, gap weights of 16, 14, 12, 10, 8, 6, or 4, and length weights of 1, 2, 3, 4, 5, or 6. The percent identity between two nucleotide or amino acid sequences can also be determined using an algorithm such as, for example, the BLASTN program for nucleic acid or amino acid sequences, which uses as defaults a word length (W) of 11, an expectation (E) of 10, M=5, N=4, and a comparison of both strands.

[0080] The constant region may be further mutated or modified by methods known in the art to alter its ability to bind to an Fc receptor.

[0081] As used herein, the term "IgG Fc region" is used to determine the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. The human IgG heavy chain Fc region is generally defined to include amino acid residues from position C226 or P230 to the carboxyl terminus of an IgG antibody. The numbering of residues in the Fc region is that of the EU index of Kabat.

[0082] Several studies to develop therapeutic antibodies have involved the engineering of the Fc region to optimize antibody properties, generating molecules that are better suited for the desired pharmacological activity. The Fc region of an antibody mediates serum half-life and effector functions such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP). Several mutations located at the junction of the CH2 and CH3 domains, such as T250Q / M428L and M252Y / S254T / T256E + H433K / N434F, have been shown to increase the binding affinity to FcRn and the half-life of IgG1 in vivo. However, there is not always a direct relationship between increased FcRn binding and improved half-life. One approach to improve the efficacy of therapeutic antibodies is to improve their serum persistence, thereby allowing higher circulating levels, less frequent administration, and smaller doses. Engineering of the Fc region may be desired to reduce or increase the effector functions of the antibody. For antibodies targeting cell surface molecules, especially those on immune cells, abrogating effector functions is required. Conversely, for antibodies intended for oncological use, enhancing effector functions may improve therapeutic activity. The four human IgG isotypes bind activating Fcγ receptors (FcγRI, FcγRIIa, FcγRIIIa), inhibitory FcγRIIb receptors, and the first component of complement (C1q) with different affinities, resulting in very different effector functions. Binding of IgG to FcγRs or C1q depends on residues located in the hinge region and the CH2 domain. Two regions of the CH2 domain are important for binding to FcγRs and C1q and have unique sequences in IgG2 and IgG4.

[0083] Other anti-SIRPg antibodies or antigen-binding fragments thereof according to the present disclosure that may be used include any antibody that contains the six CDRs of 2H9, 3H8, 26F10, 13F7, and 11B5, as set forth in Table 3 below.

[0084] [Table 3] Table 3: CDR regions of recombinant anti-SIRPg antibodies 2H9, 3H8, 26F10, 13F7 and 11B5.

[0085] For ease of reading, the CDR regions of the light and heavy chain variable domains are referred to below as VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, respectively.

[0086] The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds human SIRPg, comprising: a) a light chain variable (VL) domain comprising three CDRs, VLCDR1, VLCDR2 and VLCDR3: - VLCDR1 is selected from the group consisting of SEQ ID NO:23, SEQ ID NO:29, SEQ ID NO:35, SEQ ID NO:41, and SEQ ID NO:47; and - VLCDR2 is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:30, SEQ ID NO:36, SEQ ID NO:42, and SEQ ID NO:48; and - a VL domain in which VLCDR3 is selected from the group consisting of SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:43, and SEQ ID NO:49; and b) a heavy chain variable (VH) domain comprising three CDRs, VHCDR1, VHCDR2 and VHCDR3: - VHCDR1 is selected from the group consisting of SEQ ID NO:26, SEQ ID NO:32, SEQ ID NO:38, SEQ ID NO:44, and SEQ ID NO:50; - VHCDR2 is selected from the group consisting of SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:39, SEQ ID NO:45, and SEQ ID NO:51; and - a VH domain in which VHCDR3 is selected from the group consisting of SEQ ID NO: 28, SEQ ID NO: 34, SEQ ID NO: 40, SEQ ID NO: 46, and SEQ ID NO: 52 Includes.

[0087] In certain embodiments, an antibody or antigen-binding fragment thereof of the present disclosure comprises: a) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 23, a VLCDR2 of SEQ ID NO: 24, and a VLCDR3 of SEQ ID NO: 25; b) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 29, a VLCDR2 of SEQ ID NO: 30, and a VLCDR3 of SEQ ID NO: 31; c) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 35, a VLCDR2 of SEQ ID NO: 36, and a VLCDR3 of SEQ ID NO: 37; d) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 41, a VLCDR2 of SEQ ID NO: 42, and a VLCDR3 of SEQ ID NO: 43, or e) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 47, a VLCDR2 of SEQ ID NO: 48, and a VLCDR3 of SEQ ID NO: 49. Includes.

[0088] In more specific embodiments, the anti-SIRPg antibody or antigen-binding fragment thereof of the present disclosure has the following: a) a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 26, a VHCDR2 of SEQ ID NO: 27, and a VHCDR3 of SEQ ID NO: 28; b) a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 32, a VHCDR2 of SEQ ID NO: 33, and a VHCDR3 of SEQ ID NO: 34; c) a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 38, a VHCDR2 of SEQ ID NO: 39, and a VHCDR3 of SEQ ID NO: 40; d) a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 44, a VHCDR2 of SEQ ID NO: 45, and a VHCDR3 of SEQ ID NO: 46, or e) a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 50, a VHCDR2 of SEQ ID NO: 51, and a VHCDR3 of SEQ ID NO: 52. Includes.

[0089] In more specific embodiments, the anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure has the following: a) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 23, a VLCDR2 of SEQ ID NO: 24, and a VLCDR3 of SEQ ID NO: 25, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 26, a VHCDR2 of SEQ ID NO: 27, and a VHCDR3 of SEQ ID NO: 28; b) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 29, a VLCDR2 of SEQ ID NO: 30, and a VLCDR3 of SEQ ID NO: 31, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 32, a VHCDR2 of SEQ ID NO: 33, and a VHCDR3 of SEQ ID NO: 34; c) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 35, a VLCDR2 of SEQ ID NO: 36, and a VLCDR3 of SEQ ID NO: 37, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 38, a VHCDR2 of SEQ ID NO: 39, and a VHCDR3 of SEQ ID NO: 40; d) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 41, a VLCDR2 of SEQ ID NO: 42, and a VLCDR3 of SEQ ID NO: 43, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 44, a VHCDR2 of SEQ ID NO: 45, and a VHCDR3 of SEQ ID NO: 46, or e) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 47, a VLCDR2 of SEQ ID NO: 48, and a VLCDR3 of SEQ ID NO: 49, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 50, a VHCDR2 of SEQ ID NO: 51, and a VHCDR3 of SEQ ID NO: 52. Includes.

[0090] It is further intended that the antibody or its antigen-binding fragment may be further screened or optimized for affinity binding activity and / or antagonist activity as defined above.In particular, it is contemplated that the antibody or its antigen-binding fragment may have 1, 2, 3, 4, 5, 6 or more mutations in the amino acid sequence of 1, 2, 3, 4, 5, 6 CDRs of the monoclonal antibody provided herein.It is contemplated that the amino acid at position 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 of CDR1, CDR2, CDR3, CDR4, CDR5 or CDR6 of the VJ region or VDJ region of the light or heavy chain variable region of the antibody may have insertion, deletion, or substitution with conserved or non-conserved amino acids.Such amino acids that may be substituted or constitute substitutions are disclosed above.

[0091] In some embodiments, the difference in amino acid is a conservative substitution, i.e., a substitution of one amino acid with another amino acid with similar chemical or physical properties (size, charge or polarity), and this substitution generally does not adversely affect the biochemical, biophysical and / or biological properties of the antibody. In particular, this substitution does not disrupt the interaction of the antibody with the SIRPg antigen and the antagonistic properties. The conservative substitution is advantageously selected from one of the following five groups: group 1-small aliphatic, non-polar or slightly polar residues (A, S, T, P, G); group 2-polar, negatively charged residues and their amides (D, N, E, Q); group 3-polar, positively charged residues (H, R, K); group 4-large aliphatic, non-polar residues (M, L, I, V, C); and group 5-large aromatic residues (F, Y, W).

[0092] In a particular embodiment of the disclosure, an antibody or antigen-binding fragment thereof is disclosed as defined above by its CDR domains: a) the light chain variable domain comprises: an FR1 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 53, 61, 69, 77, and 85, an FR2 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 54, 62, 70, 78, and 86, an FR3 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 55, 63, 71, 79, and 87, and / or an FR4 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 56, 64, 72, 80, and 88; and / or b) the heavy chain variable domain comprises: an FR1 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 57, 65, 73, 81, and 89, an FR2 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 58, 66, 74, 82, and 90, an FR3 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 59, 67, 75, 83, and 91 and / or an FR4 framework amino acid sequence selected from the group consisting of SEQ ID NOs: 60, 68, 76, 84, and 92.

[0093] In a more particular embodiment, the present disclosure relates to an antibody or antigen-binding fragment thereof defined by the CDR domains as described above: a) the light chain variable domain has the following framework: - VLFR1 according to SEQ ID NO: 53, VLFR2 according to SEQ ID NO: 54, VLFR3 according to SEQ ID NO: 55 and VLFR4 according to SEQ ID NO: 56, - VLFR1 according to SEQ ID NO: 61, VLFR2 according to SEQ ID NO: 62, VLFR3 according to SEQ ID NO: 63 and VLFR4 according to SEQ ID NO: 64, - VLFR1 according to SEQ ID NO: 69, VLFR2 according to SEQ ID NO: 70, VLFR3 according to SEQ ID NO: 71 and VLFR4 according to SEQ ID NO: 72, - VLFR1 of SEQ ID NO: 77, VLFR2 of SEQ ID NO: 78, VLFR3 of SEQ ID NO: 79 and VLFR4 of SEQ ID NO: 80, or - VLFR1 according to SEQ ID NO: 85, VLFR2 according to SEQ ID NO: 86, VLFR3 according to SEQ ID NO: 87 and VLFR4 according to SEQ ID NO: 88, and / or b) the heavy chain variable domain has the following framework: - VHFR1 according to SEQ ID NO: 57, VHFR2 according to SEQ ID NO: 58, VHFR3 according to SEQ ID NO: 59 and VHFR4 according to SEQ ID NO: 60, - VHFR1 according to SEQ ID NO: 65, VHFR2 according to SEQ ID NO: 66, VHFR3 according to SEQ ID NO: 67 and VHFR4 according to SEQ ID NO: 68, - VHFR1 according to SEQ ID NO: 73, VHFR2 according to SEQ ID NO: 74, VHFR3 according to SEQ ID NO: 75 and VHFR4 according to SEQ ID NO: 76, - VHFR1 of SEQ ID NO: 81, VHFR2 of SEQ ID NO: 82, VHFR3 of SEQ ID NO: 83 and VHFR4 of SEQ ID NO: 84, or - VHFR1 according to SEQ ID NO: 89, VHFR2 according to SEQ ID NO: 90, VHFR3 according to SEQ ID NO: 91 and VHFR4 according to SEQ ID NO: 92 The amino acid sequence of

[0094] In certain embodiments, said anti-SIRPg antibody or antigen-binding fragment thereof as defined above has one or more of the following properties: (i) binds to human SIRPg, and preferably the antibody or antigen-binding fragment thereof binds to human SIRPg with an EC50 of 100 ng / ml or less, preferably 0.1 to 100 ng / ml, more particularly 5 ng / ml to 50 ng / ml, and more preferably 40 ng / ml or less, 30 ng / ml or less, 20 ng / ml or less, as may be determined by an ELISA binding assay or the methods disclosed in the Examples of the present application (see method 1.4 detailed in the Examples of the present application and the results detailed in FIG. 1 ). and / or said antibody or antigen-binding fragment thereof binds to human SIRPg with an EC50 of 3.5 μg / ml or less, particularly 3 μg / ml or less, more particularly 2.5 μg / ml or less, 2 μg / ml or less, 1.5 μg / ml or less, 1 μg / ml or less, 0.5 μg / ml or less, as may be determined by a cytofluorimetric binding assay or the methods disclosed in the Examples of the present invention (see Method 1.5 detailed in the Examples of the present application and the results detailed in Table 5 and Figure 2). (ii) does not cross-react with other SIRP members other than SIRPg, such as SIRPa and / or SIRPb, preferably SIRPa, and preferably said antibody or antigen-binding fragment thereof binds to SIRPa with an EC50 of greater than 1000 ng / ml, particularly greater than 10,000 ng / ml, as can be determined by an ELISA binding assay, more particularly binds to SIRPa with an EC50 that cannot be determined by a standard binding assay (such as an ELISA binding assay); and / or said antibody or antigen-binding fragment thereof does not inhibit SIRPa-CD47 interaction, preferably said anti-SIRPg antibody or antigen-binding fragment thereof allows less than 20% inhibition of physical binding of CD47 to SIRPa, preferably less than 10%, more preferably less than 5%, at concentrations greater than 400 ng / ml, more particularly greater than 800 ng / ml, and most particularly greater than 1000 ng / ml, as can be determined by a competitive ELISA assay. (iii) inhibits the interaction of human SIRPg with human CD47, preferably allowing greater than 60%, more preferably greater than 70%, more preferably greater than 80%, and most preferably greater than 90% inhibition of the physical binding of CD47 with SIRPg at concentrations below 1000 ng / ml, more particularly below 800 ng / ml, and most particularly below 400 ng / ml, as determined using the methods set forth in the Examples of the present application (see Method 1.6 and results in FIG. 5 detailed in the Examples); (iv) inhibiting T cell proliferation and / or T cell activation, preferably inhibiting T cell activation as assessed by analyzing IFNg secretion compared to a control known not to activate T cells, in particular said antibody or antigen-binding fragment thereof reduces or inhibits secretion of IFNg by T cells, preferably chronically activated T cells, compared to a negative control, in particular the reduction or inhibition of IFNg secretion is by more than 20%, preferably more than 30%, more preferably more than 40%, even more preferably more than 50%, even more preferably more than 60%, as assessed by any method known to the skilled person, in particular as described in the examples of the present disclosure, for example by measuring the level of IFNg secreted by T cells (e.g. chronically activated T cells) by immunoassay, in particular ELISA (see method 1.7 and Figure 6 in the examples of the present application).

[0095] The combination of properties referred to herein (antagonism of SIRPg binding to CD47; specific binding to SIRPg; no antagonist of SIRPa binding to CD47, in particular no specific binding to SIRPa and / or SIRPb, in particular no binding to SIRPa) results from binding to an epitope comprising, consisting of or located within the amino acid residues of the sequence of SEQ ID NO:1 or SEQ ID NO:2 of the anti-SIRPg antibody or antibody-binding fragment thereof of the present disclosure.

[0096] According to the present disclosure, the anti-SIRPg antibody or antigen-binding fragment thereof as described above specifically binds to a polypeptide located within or consisting solely of SEQ ID NO:1 or 2, preferably SEQ ID NO:2.

[0097] As used herein, the term "epitope" refers to the portion of an antigen to which an antibody binds. Epitopes of protein antigens are divided into two categories: conformational epitopes and linear epitopes. Conformational epitopes correspond to discontinuous portions of the amino acid sequence of an antigen. Linear epitopes correspond to a continuous sequence of amino acids of an antigen.

[0098] In certain embodiments that may be combined with the preceding embodiments, the antibody provided herein is an antibody fragment of an antibody as defined above.

[0099] Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, unibody, and scFv fragments, diabodies, single domains or nanobodies, and other fragments. Preferably, they are monovalent antibodies, such as the Fab of an scFv fragment.

[0100] The term "diabody" refers to a small antibody fragment with two antigen-binding sites, which comprises a heavy chain variable domain (VH) linked in the same polypeptide chain (VH-VL) with a light chain variable domain (VL). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementary domains of another chain, forming two antigen-binding sites.

[0101] A single domain antibody is an antibody fragment that contains all or a portion of the heavy chain variable domain of an antibody, or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single domain antibody is a human single domain antibody (Domantis, Inc. Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1). Antibody fragments can be produced by a variety of techniques, including, but not limited to, proteolytic digestion of intact antibodies, as well as production by recombinant host cells as described herein.

[0102] Nucleic Acids Encoding SIRPg Antibodies

[0103] Also disclosed herein are nucleic acid molecules encoding the anti-SIRPg antibodies or antigen-binding fragments of the disclosure.

[0104] Typically, the nucleic acid is a DNA or RNA molecule and can be contained in any suitable vector, such as a plasmid, cosmid, episome, artificial chromosome, phage or viral vector. As used herein, the terms "vector", "cloning vector" and "expression vector" refer to a vehicle that can introduce a DNA or RNA sequence (e.g., a foreign gene) into a host cell, transform the host and promote the expression (e.g., transcription and translation) of the introduced sequence. Thus, a further object of the present disclosure relates to a vector that contains the nucleic acid described herein.

[0105] An example of an isolated nucleic acid molecule or combination of isolated nucleic acid molecules is one that encodes the amino acid sequence of the variable light and heavy chains of the anti-SIRPg antibodies disclosed in the previous section, using the genetic code and optionally taking into account codon bias depending on the host cell type.

[0106] In certain embodiments, the disclosure relates to a first isolated nucleic acid molecule comprising or consisting solely of a sequence encoding a variable light chain selected from the group consisting of SEQ ID NOs: 93, 95, 97, 99, and 101; and / or a second isolated nucleic acid molecule comprising or consisting solely of a sequence encoding a variable heavy chain selected from SEQ ID NOs: 94, 96, 98, 100, and 102. In certain embodiments, the sequences encoding the variable light and heavy chains are comprised in the same nucleic acid molecule.

[0107] Typically, the disclosure relates to a first and second nucleic acid molecule encoding the variable heavy and light chains, respectively, of the 2H9 antibody comprising or consisting of the sequences of SEQ ID NO:93 and SEQ ID NO:94, a first and second nucleic acid molecule encoding the variable heavy and light chains, respectively, of the 3H8 antibody comprising or consisting of the sequences of SEQ ID NO:95 and SEQ ID NO:96, a first and second nucleic acid molecule encoding the variable heavy and light chains, respectively, of the 26F10 antibody comprising or consisting of the sequences of SEQ ID NO:97 and SEQ ID NO:98, a first and second nucleic acid molecule encoding the variable heavy and light chains, respectively, of the 13F7 antibody comprising or consisting of the sequences of SEQ ID NO:99 and SEQ ID NO:100, and a first and second nucleic acid molecule encoding the variable heavy and light chains, respectively, of the 11B5 antibody comprising or consisting of the sequences of SEQ ID NO:101 and SEQ ID NO:102. In certain embodiments, the sequences encoding the variable light and heavy chains are comprised in the same nucleic acid molecule.

[0108] In certain embodiments of the present disclosure, the first and second nucleic acid molecules encoding the variable heavy and light chain regions of the antibody as described above may be associated with nucleic acid sequences encoding heavy and light chain constant regions, respectively, and preferably comprise the nucleotide sequences of SEQ ID NOs: 135 and 136, respectively.

[0109] In another specific embodiment, the present disclosure relates to a first nucleic acid molecule encoding a light chain variable (VL) domain comprising three nucleic acid sequences encoding the three CDRs VLCDR1, VLCDR2, and VLCDR3 of 2H9, 3H8, 26F10, 13F7, and 11B5, preferably the first nucleic acid molecule encoding a VLCDR1 selected from the group consisting of SEQ ID NOs: 105, 111, 117, 123, and 129, a VLCDR2 selected from the group consisting of SEQ ID NOs: 106, 112, 118, 124, and 130, and a VLCDR3 selected from the group consisting of SEQ ID NOs: 107, 113, 119, 125, and 131. and a second nucleic acid molecule encoding a heavy chain variable (VH) domain comprising three nucleic acid sequences encoding the three CDRs VHCDR1, VHCDR2 and VHCDR3 of 2H9, 3H8, 26F10, 13F7 and 11B5, preferably said second nucleic acid molecule is a nucleic acid sequence encoding a VHCDR1 selected from the group consisting of SEQ ID NOs: 108, 114, 120, 126 and 132, a nucleic acid sequence encoding a VHCDR2 selected from the group consisting of SEQ ID NOs: 109, 115, 121, 127 and 133 and a nucleic acid sequence encoding a VHCDR3 selected from the group consisting of SEQ ID NOs: 110, 116, 122, 128 and 134. In a particular embodiment, the sequences encoding the variable light and heavy chains are comprised in the same nucleic acid molecule.

[0110] In a preferred embodiment, the present disclosure provides: - a first nucleic acid molecule encoding a light chain variable (VL) domain comprising three nucleic acid sequences encoding the three CDRs VLCDR1, VLCDR2 and VLCDR3 of 2H9 (respectively SEQ ID NOs: 105 to 107), and a second nucleic acid molecule encoding a heavy chain variable (VH) domain comprising three nucleic acid sequences encoding the three CDRs VHCDR1, VHCDR2 and VHCDR3 of 2H9 (respectively SEQ ID NOs: 108 to 110); - a first nucleic acid molecule encoding a light chain variable (VL) domain comprising three nucleic acid sequences encoding the three CDRs VLCDR1, VLCDR2 and VLCDR3 of 3H8 (respectively SEQ ID NOs: 111 to 113), and a second nucleic acid molecule encoding a heavy chain variable (VH) domain comprising three nucleic acid sequences encoding the three CDRs VHCDR1, VHCDR2 and VHCDR3 of 3H8 (respectively SEQ ID NOs: 114 to 116); - a first nucleic acid molecule encoding a light chain variable (VL) domain comprising three nucleic acid sequences encoding the three CDRs VLCDR1, VLCDR2 and VLCDR3 of 26F10 (respectively SEQ ID NOs: 117 to 119), and a second nucleic acid molecule encoding a heavy chain variable (VH) domain comprising three nucleic acid sequences encoding the three CDRs VHCDR1, VHCDR2 and VHCDR3 of 26F10 (respectively SEQ ID NOs: 120 to 122); - a first nucleic acid molecule encoding a light chain variable (VL) domain comprising three nucleic acid sequences encoding the three CDRs VLCDR1, VLCDR2 and VLCDR3 of 13F7 (respectively SEQ ID NOs: 123 to 125), and a second nucleic acid molecule encoding a heavy chain variable (VH) domain comprising three nucleic acid sequences encoding the three CDRs VHCDR1, VHCDR2 and VHCDR3 of 13F7 (respectively SEQ ID NOs: 126 to 128), or - a first nucleic acid molecule encoding a light chain variable (VL) domain comprising three nucleic acid sequences encoding the three CDRs VLCDR1, VLCDR2, and VLCDR3 of 11B5 (respectively SEQ ID NOs: 129 to 131), and a second nucleic acid molecule encoding a heavy chain variable (VH) domain comprising three nucleic acid sequences encoding the three CDRs VHCDR1, VHCDR2, and VHCDR3 of 11B5 (respectively SEQ ID NOs: 132 to 134). Regarding.

[0111] In certain embodiments, the sequences encoding the variable light and heavy chains are contained in the same nucleic acid molecule.Nucleic acids encoding the anti-SIRPg antibodies of the present disclosure having a nucleotide sequence that has at least 90%, such as at least 95%, 96%, 97%, 98%, or 99% identity to any one of the above-defined nucleotide sequences are also part of the present disclosure.

[0112] The present disclosure also relates to nucleic acid molecules derived from the latter sequence that are optimized for protein expression in mammalian cells, such as CHO or HEK cell lines.

[0113] The polynucleotide, vector or cell of the present disclosure is useful for producing the protein of the present invention using well-known recombinant DNA technology. The polynucleotide according to the present disclosure is prepared by standard methods known in the art. For example, it is produced by amplifying nucleic acid sequences by PCR or RT-PCR, by screening genomic DNA libraries by hybridization with homologous probes, or by total or partial chemical synthesis. The recombinant vector is constructed and introduced into host cells by conventional recombinant DNA and genetic engineering techniques known in the art.

[0114] host cell

[0115] A further object of the present disclosure relates to host cells transfected, infected or transformed by the nucleic acids and / or vectors according to the invention. As used herein, the term "transformation" means the introduction of a "foreign" (i.e., exogenous, or extracellular) gene, DNA or RNA sequence into a host cell such that the host cell expresses the introduced gene or sequence to produce a desired substance, typically a protein or enzyme encoded by the introduced gene or sequence. A host cell that receives and expresses the introduced DNA or RNA is said to be "transformed".

[0116] The host cell may be a eukaryotic cell, such as a mammalian cell, including monkey, human, canine and rodent cells. Mammalian host cells for expressing the antibodies of the disclosure include Chinese Hamster Ovary (CHO) cells, including dhfr-CHO cells (described in Urlaub and Chasin, 1980) used with a DHFR selectable marker (described in Kaufman and Sharp, 1982), CHOK1 dhfr+ cell line, NSO myeloma cells, COS cells and SP2 cells, such as GS Xceed cells. TM Examples include GS CHO cell line, HEK-293 cells (ATCC CRL-1573) used with a gene expression system (Lonza). In a preferred embodiment, the host cell is a CHO cell or a HEK-293 cell.

[0117] Methods for Producing Antibodies

[0118] The antibodies of the present disclosure can be produced in host cell transfectomas, for example, using a combination of recombinant DNA technology and gene transfer methods, as is well known in the art (Morrison, 1985). To express the light and heavy chains, expression vectors encoding the heavy and light chains are transfected into the host cells by standard techniques. The various forms of the term "transfection" are intended to encompass the various techniques commonly used to introduce foreign DNA into prokaryotic or eukaryotic host cells, such as electroporation, calcium phosphate precipitation, DEAE-dextran transfection, and the like. Once a recombinant expression vector encoding an antibody gene has been introduced into a mammalian host cell, the antibody is produced by culturing the host cell for a period of time sufficient for expression of the antibody in the host cell, and, optionally, secretion of the antibody into the culture medium in which the host cell is growing. The antibody can be recovered and purified from the culture medium after secretion, for example, using standard protein purification methods (Shukla et al., 2007).

[0119] Pharmaceutical Compositions

[0120] In another aspect, the disclosure provides a composition, e.g., a pharmaceutical composition, comprising an antibody, antigen-binding fragment thereof, isolated nucleic acid molecule and / or a combination of isolated nucleic acid molecules disclosed herein, e.g., an antibody or antigen-binding fragment thereof selected from the group consisting of 2H9, 3H8, 26F10, 13F7, and 11B5, or a nucleic acid molecule encoding said antibody or antigen-binding fragment, formulated together with a pharma- ceutically acceptable carrier.

[0121] As used herein, the term "pharmaceutical acceptable" means approved by a regulatory agency or an official pharmacopoeia, such as the European Pharmacopoeia, for use in animals and / or humans. The term "excipient" refers to a diluent, adjuvant, carrier, or vehicle with which a therapeutic agent is administered.

[0122] Any suitable pharma- ceutically acceptable carrier, diluent or excipient can be used to prepare pharmaceutical compositions (see, for example, Remington: The Science and Practice of Pharmacy, Alfonso R. Gennaro (ed.) Mack Publishing Company, April 1997). Pharmaceutical compositions are usually sterile and stable under the conditions of manufacture and storage. Pharmaceutical compositions can be formulated as solutions (e.g., saline, glucose solution, buffer solution, or other pharma- ceutically acceptable sterile liquids), microemulsions, liposomes, or other ordered structures (e.g., microparticles or nanoparticles) suitable for accommodating high concentrations of the product. The carrier can be, for example, a solvent or dispersion medium containing water, ethanol, polyol (e.g., glycerol, propylene glycol, liquid polyethylene glycol, and the like), and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size, and, in the case of dispersions, by the use of surfactants. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, sodium chloride in the composition.

[0123] In one embodiment, the pharmaceutical composition is a parenteral pharmaceutical composition, including compositions suitable for intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular administration. These pharmaceutical compositions are merely examples and are not limiting of pharmaceutical compositions suitable for other parenteral and oral administration routes. The pharmaceutical compositions described herein can be packaged in single unit dose or multi-dose form.

[0124] Preferably, the pharmaceutical composition comprises a pharma- ceutically acceptable vehicle for injectable preparations, which may in particular be an isotonic solution, a sterile solution, a saline solution (monosodium or disodium phosphate, sodium chloride, potassium chloride, calcium chloride or magnesium chloride, etc., or a mixture of these salts), or a dried, in particular lyophilized, composition, which may be constituted by adding sterile water or physiological saline, if necessary, to form an injectable solution.

[0125] therapeutic use

[0126] Antagonist anti-SIRPg antibodies or antigen-binding fragments thereof can reduce or inhibit the proliferation and / or activation of T cells, thus promoting an immunosuppressive environment and being useful in the treatment of any disease in which T cells have a deleterious effect, particularly autoimmune diseases, transplant dysfunction, and inflammatory diseases. Indeed, while the immune response is a normal host defense response against injury and disease, it can also cause unwanted damage when directed against the host's cells.

[0127] In a particular aspect, the present disclosure provides the use of the antibody, antigen-binding fragment thereof, isolated nucleic acid molecule, combination of isolated nucleic acid molecules, and / or pharmaceutical composition according to any one of the preceding embodiments for the treatment, preferably for the treatment, prevention, or inhibition of progression of a disease in which T cells have a deleterious effect, in particular an autoimmune disease, an inflammatory disease such as a chronic inflammatory disease, a chronic neuroinflammatory disease, an immunometabolic disease, a cardiovascular disease caused by systemic inflammation, or transplant dysfunction.

[0128] A disease or disorder in which T cells have a detrimental effect may therefore include any disease or disorder in which T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells has a detrimental effect, preferably a disease or disorder in which T cell proliferation and / or activation has a detrimental effect.

[0129] Diseases that can be treated with immunosuppressants, and thus with an anti-SIRPg antibody or antigen-binding fragment thereof according to the present disclosure, are well known in the art, and in particular diseases or disorders in which T cells have a detrimental effect include the following: - Autoimmune diseases, especially rheumatoid arthritis, type I diabetes, lupus, psoriasis, - inflammatory diseases, for example chronic inflammatory diseases, in particular inflammatory bowel disease, including Crohn's disease and ulcerative colitis; or chronic neuroinflammatory diseases, in particular multiple sclerosis, encephalomyelitis, - immunometabolic diseases, especially type II diabetes, - Cardiovascular diseases, especially atherosclerosis, caused by systemic inflammation; and - Transplant dysfunction or rejection, especially graft-versus-host disease, - Lymphoproliferative disorders, especially T-cell lymphoma or post-transplant lymphoproliferative disorders The compound may be selected from the group consisting of:

[0130] In a particular embodiment, the disease or disorder in which T cell proliferation and / or activation and / or migration and / or tissue infiltration has a detrimental effect is a transplant dysfunction, in particular graft-versus-host disease, in particular T cell lymphoma or post-transplant lymphoproliferative disorder.

[0131] As used herein, the term "subject" or "patient" refers to a mammal. Mammalian species that can benefit from the disclosed therapeutic methods include, but are not limited to, humans, non-human primates such as apes, chimpanzees, monkeys, and orangutans, domesticated animals including dogs and cats, and livestock such as horses, cows, pigs, sheep, and goats, or other mammalian species including, but not limited to, mice, rats, guinea pigs, rabbits, hamsters, etc.

[0132] As used herein, the terms "therapy," "treat," or "treating" refer to any action intended to improve the health status of a patient, such as the cure, prevention, prophylaxis, and delay of disease. In certain embodiments, such terms refer to the amelioration or eradication of a disease or symptoms associated with a disease, e.g., according to the present disclosure, the promotion of an immunosuppressive environment, in particular the prevention or inhibition of T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells. In other embodiments, the terms refer to minimizing the spread or worsening of a disease caused by the administration of one or more therapeutic agents to a subject with such a disease.

[0133] In a further embodiment, the present invention relates to a method for treating, preventing or alleviating a disease or disorder in which T cells have a detrimental effect as described above in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the above-mentioned antibody and / or antigen-binding fragment thereof and / or isolated nucleic acid molecule and / or combination of isolated nucleic acid molecules and / or pharmaceutical composition.

[0134] In a further aspect, the present disclosure relates to a method for treating a disease comprising administering to a patient in need thereof a therapeutically effective amount of an anti-SIRPg antibody and / or antigen-binding fragment thereof and / or an isolated nucleic acid molecule and / or a combination of isolated nucleic acid molecules and / or a pharmaceutical composition according to the present disclosure, said disease being selected from the group consisting of: autoimmune diseases, inflammatory diseases, immunometabolic diseases, cardiovascular diseases caused by systemic inflammation, and transplant failure or rejection, in particular by inhibiting T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells.

[0135] In a further aspect, the present disclosure relates to a method for treating a disease comprising administering a therapeutically effective amount of an anti-SIRPg antibody and / or antigen-binding fragment thereof and / or an isolated nucleic acid molecule and / or a combination of isolated nucleic acid molecules and / or a pharmaceutical composition according to the present disclosure to a patient in need thereof, wherein said disease is selected from the group consisting of: autoimmune diseases, inflammatory diseases, immunometabolic diseases, cardiovascular diseases caused by systemic inflammation, and transplant failure or rejection, and wherein said disease is related to T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells.

[0136] In a further embodiment, the subject has a disease selected from the group consisting of an autoimmune disease, an inflammatory disease, an immunometabolic disease, a cardiovascular disease resulting from systemic inflammation, and transplant dysfunction or rejection, which is associated with T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells.

[0137] In the context of the present invention, an "effective amount" refers to an amount that is therapeutically effective. As used herein, a "therapeutically effective amount" refers to an amount that is effective at the dosages and for the duration necessary to achieve a desired therapeutic outcome, such as the prevention or treatment of a disease or disorder in which T cells have a detrimental effect. The therapeutically effective amount of the product of the present invention or the pharmaceutical composition it contains may vary depending on factors such as the disease state, age, sex, weight, etc. of the individual, and the ability of the product or pharmaceutical composition to obtain a desired response in the individual. Dosage regimens may be adjusted to provide an optimal therapeutic response. A therapeutically effective amount is also typically an amount in which the toxic or adverse effects of the product or pharmaceutical composition are outweighed by the therapeutically beneficial effects.

[0138] The products of the present disclosure will typically be included in a pharmaceutical composition or medicament, optionally in combination with a pharmaceutical carrier, diluent and / or adjuvant. Such a composition or pharmaceutical product will contain an effective amount of the product of the present disclosure sufficient to provide the desired therapeutic effect, and a pharma- ceutically acceptable carrier or excipient.

[0139] In one embodiment, the antibody and / or antigen-binding fragment thereof, and / or the isolated nucleic acid molecule and / or the combination of isolated nucleic acid molecules, and / or the pharmaceutical composition for therapeutic use is administered to a subject or patient by a parenteral route, in particular by an intravenous, intraarterial, subcutaneous, intraperitoneal, or intramuscular route.

[0140] The amount of the product of the present disclosure administered to a subject or patient may vary depending on the particular circumstances of the individual subject or patient, including the age, sex, and weight of the individual, the nature and stage of the disease, the aggressiveness of the disease, the route of administration, and / or any concomitant medications prescribed to the subject or patient. Dosage regimens may be adjusted to provide the optimal therapeutic response.

[0141] For any particular subject, specific dosage regimens may be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Dosage ranges set forth herein are exemplary only and do not limit the dosage ranges that may be selected by health care practitioners.

[0142] The antibodies or antigen-binding fragments thereof, isolated nucleic acid molecules, combinations of isolated nucleic acid molecules, and / or pharmaceutical compositions thereof may be provided in an effective amount of about 1 ng / kg body weight to about 30 mg / kg body weight, or more. In specific embodiments, dosages may range from 1 μg / kg to about 20 mg / kg, optionally 10 μg / kg to 10 mg / kg, or 100 μg / kg to 5 mg / kg (kg: body weight of the subject or patient).

[0143] In certain embodiments of the methods, administration of the anti-SIRPg antibodies, antigen-binding fragments thereof, isolated nucleic acid molecules, combinations of isolated nucleic acid molecules, and / or pharmaceutical compositions thereof of the present disclosure reduces or inhibits T cell proliferation by more than 20%, more particularly more than 50%, and most preferably more than 70% compared to a negative control.

[0144] In another specific embodiment, administration of the anti-SIRPg antibody, antigen-binding fragment thereof, isolated nucleic acid molecule, combination of isolated nucleic acid molecules, and / or pharmaceutical composition thereof of the present disclosure inhibits activation of T cells, in particular inhibits secretion of interferon gamma (IFNg) cytokine by T cells, in particular reduces or inhibits IFNg secretion by T cells compared to a negative control, in particular reduces or inhibits IFNg secretion by more than 20%, preferably more than 30%, preferably more than 40%, more preferably more than 50%. The negative control can be medium without the antibody or an antibody known not to activate T cells.

[0145] The present disclosure also relates to the use of a specific anti-SIRPg antibody, antigen-binding fragment thereof, isolated nucleic acid molecule, combination of isolated nucleic acid molecules, and / or pharmaceutical composition according to the present disclosure in the manufacture of a medicament for the prevention and / or treatment of a disease or disorder in which T cells have a deleterious effect, particularly a human disease or disorder, as described above.

[0146] In a further aspect, the present invention relates to a method for inhibiting a T cell response, in particular T cell proliferation and / or T cell activation and / or T cell migration and / or tissue infiltration by T cells, more particularly IFNg secretion (by T cells and / or NK cells, in particular T cells, more particularly chronically activated T cells), comprising: - selecting patients with disorders in which T cells have a detrimental effect; and - administering to said patient an effective amount of an anti-SIRPg antibody and / or antigen-binding fragment thereof and / or an isolated nucleic acid molecule and / or a combination of isolated nucleic acid molecules and / or a pharmaceutical composition according to the present disclosure. Includes.

[0147] In a further aspect, the present invention relates to a method for inhibiting T cell responses, in particular T cell proliferation and / or T cell activation and / or T cell migration and / or tissue infiltration by T cells, more particularly IFNg secretion (by T cells and / or NK cells, in particular T cells, more particularly chronically activated T cells), which method comprises administering to a subject in need thereof an effective amount of an anti-SIRPg antibody and / or antigen-binding fragment thereof and / or an isolated nucleic acid molecule and / or a combination of isolated nucleic acid molecules and / or a pharmaceutical composition according to the present disclosure.

[0148] In particular, the patient has a disease selected from the group consisting of an autoimmune disease, an inflammatory disease, an immunometabolic disease, a cardiovascular disease resulting from systemic inflammation, and transplant dysfunction or rejection.

[0149] In a further embodiment, the patient has a disease selected from the group consisting of an autoimmune disease, an inflammatory disease, an immunometabolic disease, a cardiovascular disease caused by systemic inflammation, and a transplant dysfunction or rejection reaction associated with T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells.

[0150] Combination Products

[0151] The anti-SIRPg antibodies, antigen-binding fragments thereof, isolated nucleic acid molecules, combinations of isolated nucleic acid molecules, and / or pharmaceutical compositions can be administered alone or in combination with another therapeutic agent, such as a second human monoclonal antibody or antigen-binding fragment thereof. For example, the anti-SIRPg antibodies, antigen-binding fragments thereof, isolated nucleic acid molecules, combinations of isolated nucleic acid molecules, and / or pharmaceutical compositions are administered with another agent, such as an immunotherapeutic agent, an immunosuppressant, an erythropoietin agent (ESA), a proapoptotic agent, an antibiotic, a probiotic, a combination with a therapeutic cell composition, and the like.

[0152] In one embodiment, the present disclosure relates to the above-mentioned anti-SIRPg antibody, antigen-binding fragment thereof, isolated nucleic acid molecule, combination of isolated nucleic acid molecules, and / or pharmaceutical composition for the uses described above, wherein the above-mentioned anti-SIRPg antibody, antigen-binding fragment thereof, isolated nucleic acid molecule, combination of isolated nucleic acid molecules, and / or pharmaceutical composition is combined with a second therapeutic agent.

[0153] The administration of the second drug may or may not be simultaneous with the administration of a particular product according to the present disclosure. Depending on the nature of the second drug, the co-administered drug may be prepared in the form of a combination drug, also known as a "combo." A combo is a fixed-dose combination drug, containing two or more active pharmaceutical ingredients combined in a single dosage form, manufactured and dispensed in a fixed dose. However, the dosage regimen and route of administration may differ.

[0154] In preferred embodiments, the second therapeutic agent is selected from the group consisting of immunotherapeutic agents, immunosuppressants, proapoptotic agents, antibiotics, and probiotics.

[0155] In preferred embodiments, the second therapeutic agent is an immunosuppressant selected from the group consisting of cyclosporin A, tacrolimus, mycophenolate mofetil, rapamycin, steroids, anti-TNF agents, and anti-IL-23 agents.

[0156] The present disclosure also provides: - the specific anti-SIRPg antibodies, antigen-binding fragments thereof, isolated nucleic acid molecules, combinations of isolated nucleic acid molecules, and / or pharmaceutical compositions as described above, and - a second therapeutic agent selected from the group consisting of immunotherapeutic agents, immunosuppressants, proapoptotic agents, antibiotics, and probiotics; for simultaneous, separate or sequential use as a medicine, in particular for the prevention and / or treatment of diseases or disorders in which activation and / or proliferation of T cells has a detrimental effect.

[0157] Administration for such purposes can be repeated as needed, for example daily, semi-weekly, weekly, semi-monthly, monthly, or upon recurrence as needed.

[0158] kit

[0159] In another aspect, the present disclosure further relates to a kit comprising the antibody or antigen-binding fragment, nucleic acid, host cell or pharmaceutical composition of the present invention in one or more containers. The kit may comprise instructions or packaging material that describes how to administer the product contained in the kit to a patient. The container of the kit may be any suitable material, such as glass, plastic, metal, etc., and any suitable size, shape, or construction. In certain embodiments, the kit may comprise one or more ampoules or syringes that contain the product of the present invention in a suitable liquid or solution form.

[0160] The present invention will now be illustrated by the following non-limiting examples with reference to the accompanying figures. EXAMPLES

[0161] 1. Method

[0162] 1.1 Preparation, selection and characterization of mouse anti-human SIRPg monoclonal antibodies

[0163] Mice were immunized with human SIRPg His (recombinant human SIRPg protein with His tag, #11828-H08H, Sino Biological) to induce monoclonal antibodies according to standard methods. The immunization protocol was performed by Diaclone SAS (Besancon, France): 1 μg of human SIRPg protein was administered by footpad technique to three BALB / c strain mice, one day per week for the first three injections, the fourth injection two weeks later, and the last injection one week later. The fifth injection on day 35 was considered as a boost before harvesting ganglion cells. Hybridomas were obtained by fusing ganglion cells with mouse myeloma X63 / AG.8653. The hybridomas were first screened by the ability of the secreted monoclonal antibodies to specifically bind to biotinylated human SIRPg protein (#11828-H08H, Sino Biological, biotin was conjugated by DiaClone) and to specifically bind to human SIRPg protein on the surface of human T lymphocyte Jurkat cell line. The hybridomas were then confirmed to have secreted monoclonal antibodies that specifically bind to biotinylated human SIRPg protein but not to human SIRPa His (recombinant human SIRPa protein with His tag, #11612-H08H, Sino Biological), and to Jurkat cells but not to SIRPa positive U937 human monocytic cell line and negative control RAJI human B lymphoma cell line. After selection, the hybridomas were cloned and cultured in RPMI complete medium. The supernatant was purified by Protein A affinity chromatography (DiaClone, Besancon, France) using glycine 0.1 M pH 2.8 elution buffer. The activity of the purified antibodies was measured by ELISA against human SIRP proteins and by flow cytometry assays against SIRP cell lines and primary human blood cells.

[0164] 1.2 Preparation of chimeric antibodies

[0165] To construct the heavy chain of the anti-SIRP gamma Ab, the variable domain VH was synthesized from the 2H9, 3H8, 11B5, 13F7 or 26F10 sequence and cloned with EcoRV into the pcDNA3.4CHIg-hG4m expression plasmid (pcDNA3.4 vector, Invitrogen, Toulouse) containing the Fc of human IgG4 mutated (S228P) to stabilize the hinge region. To construct the light chain of the anti-SIRP gamma Ab, the same variable domain VL was synthesized from the 2H9, 3H8, 11B5, 13F7 or 26F10 sequence and cloned with BsiWI into the pcDNA3.4CLIg-hk expression plasmid (pcDNA3.4 vector, Invitrogen, Toulouse) containing the human CLkappa. In HEK 293 Freestyle cells, we co-introduced plasmids containing VH2H9-FcG4, VH3H8-FcG4, VH11B5-FcG4, VH13F7-FcG4, or VH26F10-FcG4 with plasmids containing VL-CLkappa by the lipofectamine method. After incubation for 6 days, the supernatants were collected and purified by Protein A affinity chromatography (HiTrap, GE healthcare) using 0.1M citrate pH 3 elution buffer. The purified antibodies were dialyzed against PBS and concentrated. They were quantified by UV (A280nm) and tested in an activity assay against SIRPg.

[0166] 1.3 ELISA SIRPa binding assay of chimeric antibodies

[0167] For human SIRPa binding assays, recombinant human SIRPa (#11612-H08H, Sino Biological) was immobilized on plastic at 0.5 μg / ml (SIRPa) in carbonate buffer (pH 9.2). After saturation, purified antibodies were added in a range (from an initial concentration of 10 μg / ml) and binding was measured. After incubation and washing, peroxidase-labeled donkey anti-human IgG (#709-035-149, Jackson Immunoresearch) was added and visualized by standard methods.

[0168] 1.4 ELISA human SIRPg binding assay for chimeric antibodies

[0169] For human SIRPg binding assays, purified antibodies were captured at a range (from an initial concentration of 5 μg / ml) with immobilized coated donkey anti-human IgG (H+L) (#709-005-098, Jackson Immunoresearch) at 2 μg / ml in borate buffer. After washing, biotinylated SIRPg (#11828-H08H, Sino Biological, biotinylation performed by Ose Immunotherapeutics) was added at 1 μg / ml and visualized with streptavidin-peroxidase (#016-030-084, Jackson Immunoresearch).

[0170] 1.5 Human SIRPg binding assay to human Jurkat by cytofluorometry

[0171] To measure binding of mouse anti-hSIRPg to human cell lines, cells were first washed with cold PSE (phosphate-buffered saline with 2% heat-inactivated bovine serum, 2 mM EDTA) and blocked with a mixture of 1:50 diluted human Fc-block (#564220, BD Pharmingen) and 1:20 diluted heat-inactivated human serum (SAB, #H4522-100, Sigma Aldrich) for 30 min at room temperature, then incubated on ice for 10 min to slow down cell metabolism. A range of antibodies were incubated on ice for 30 min, cells were washed with cold PSE and then stained with 5 μg / ml Alexa 647-conjugated goat anti-mouse IgG (#A21236; Fisher Scientific, Illkirch, France) for 30 min on ice. Samples were analyzed on a CytoFlex cytofluorometer (Beckman Coulter France, Villepinte).

[0172] 1.6 Antagonistic activity of human SIRPg and human SIRPa measured by ELISA

[0173] For antagonist activity ELISA assays, recombinant human SIRPg (#11828-H08H, Sino Biological) or recombinant human SIRPa (#11612-H08H, Sino Biological) were immobilized on plastic in carbonate buffer (pH 9.2) at 2 μg / ml (SIRPg) and 0.5 μg / ml (SIRPa), respectively. During saturation, biotinylated human CD47 (#CD7-H82F6, Acrobio) was pre-incubated with a range of purified antibodies at their own concentrations (final concentration 3 μg / ml) for 15 min at room temperature. The pre-incubated [CD47-biot / purified antibody] mixture was then incubated on immobilized SIRPg (O / N at room temperature) or on immobilized SIRPa (2 h at 37°C). After incubation and washing, streptavidin-peroxidase (#016-030-084, Jackson Immunoresearch) was added and visualized by standard methods.

[0174] 1.7 Functional analysis

[0175] For exhausted T cells, PBMCs were stimulated in complete medium in triplicate in plates coated with 3μg / ml anti-CD3 (OKT3) and 3μg / ml soluble anti-CD28.2. For functional assays, exhausted or unstimulated PBMCs were activated in plates coated with 0.5μg / ml anti-CD3 (OKT3) and 10μg / ml human CD47Fc recombinant protein (#12283-H02H, SinoBiological). Antibodies were then incubated with exhausted or unstimulated PBMCs on plates for 2 days to measure IFNg secretion (#555142, BDBiosciences) and proliferation was measured by AlamarBlue detection at 530nm (#DAL1100, Invitrogen) after 5 days of incubation at 37℃, 5%CO2.

[0176] 2.Results

[0177] 2.1 Higher productivity of 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies

[0178] The productivity of the 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies was compared to the prior art A1, A5, and A8 antibodies (WO2020 / 039049). The production yields in mammalian cells are shown in Table 4 below: [Table 4]

[0179] The production yields of the 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies are 100-100,000 times higher than that of the prior art anti-SIRPg antibodies A1, A5, and A8, making them suitable for clinical use.

[0180] 2.2 High binding affinity of 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies to SIRPg

[0181] The binding affinities of purified 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies measured in an ELISA human SIRPg binding assay were compared with the prior art antibodies Kwar23 (made in-house based on the sequence disclosed in International Application WO2015 / 138600), A1, and A5 antibodies. As shown in Figure 1, the 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies showed similar binding affinities to the anti-SIRPα and γKwar23 antibodies, and showed higher binding affinities to SIRPg compared to the prior art A1 and A5 antibodies.

[0182] The binding affinity of purified 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies to human Jurkat cells was compared with the prior art LSB2.20 (Biolegend, ref. 336602) and OX119 antibodies (SantaCruz ref. sc-53114). As shown in FIG. 2 and Table 5 below, the binding affinity of 2H9, 3H8, 11B5, 26F10, and 13F7 to SIRPg, as measured in a human SIRPg binding assay on human Jurkat cells by cytofluorometry, is higher than that of the prior art LSB2.20 and OX119 antibodies.

[0183] [Table 5] Table 5: Human SIRPg binding assay on human Jurkat by cytofluorometry. The ED50, also called EC50, is the concentration of antibody that reaches 50% of the signal in this assay.

[0184] 2.3 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies are SIRPg specific (do not bind SIRPa and have no antagonist activity towards SIRPa-CD47 interaction)

[0185] To examine the cross-reactivity of the 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies, an ELISA SIRPa binding assay was performed. As shown in Figure 3, the Kwar23 antibody showed binding affinity to SIRPa, while the 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies did not bind to SIRPa. These results were confirmed by binding assay to U937 cells and BLITZ assay, as shown in Table 6 below: [Table 6]

[0186] Human SIRPa antagonist activity against SIRPa-CD47 interaction was measured by ELISA. As shown in Figure 4, anti-SIRPα antibody and γKwar23 antibody inhibited SIRPa-CD47 interaction, as did OX119 antibody to a lesser extent, while 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies did not inhibit SIRPa-CD47 interaction.

[0187] These results indicate that the 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies selectively bind to SIRPg and do not cross-react with SIRPa. Indeed, these antibodies do not bind to human SIRPa or exhibit antagonist activity against the human SIRPa-CD47 interaction.

[0188] 2.4 Efficient SIRPg antagonist activity of 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies against SIRPg-CD47 interaction

[0189] The human SIRPg antagonist activity of 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies against SIRPg-CD47 interaction was measured by ELISA. As shown in Figure 5, 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies effectively inhibited SIRPg-CD47 interaction.

[0190] 2.5 Functional Analysis - Inhibition of T Cell Activation by 2H9, 3H8, 11B5, 26F10, and 13F7 Antibodies

[0191] In the biological assay, CD47-dependent pre-activated PBMCs (CD3-CD28) were stimulated on CD47 and anti-CD3 coating. The cells induced the secretion of IFNg cytokine in the supernatant. In this CD47-dependent biological assay, as shown in Figure 6, the inventors observed that anti-SIRPg 2H9, 3H8, 11B5, 26F10, and 13F7 antibodies, as well as anti-SIRPα and γKwar23 antibodies (antagonists of SIRPa-CD47 interaction), could efficiently inhibit the secretion of IFNg, in contrast to the prior art LSB2.20 and OX119 antibodies. [Industrial Applicability]

[0192] In conclusion, unlike the antibodies of the prior art, the antibodies of the present disclosure can be produced in high yields suitable for clinical use, and furthermore, they selectively bind to SIRPg, do not cross-react with SIRPa, and are not antagonists of SIRPa-CD47 interaction, but are potent inhibitors of SIRPg-CD47 interaction.The antagonistic activity of the antibodies of the present disclosure against SIRPg-CD47 interaction reduces the activation of T cells, as shown by the reduction of IFNg secretion.Therefore, the antibodies are suitable for the prevention and treatment of diseases in which T cells have a harmful effect.

Claims

1. 1. An anti-SIRPg antibody or antigen-binding fragment thereof that specifically binds to human SIRPg: a) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 23, a VLCDR2 of SEQ ID NO: 24, and a VLCDR3 of SEQ ID NO: 25, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 26, a VHCDR2 of SEQ ID NO: 27, and a VHCDR3 of SEQ ID NO: 28; b) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 29, a VLCDR2 of SEQ ID NO: 30, and a VLCDR3 of SEQ ID NO: 31, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 32, a VHCDR2 of SEQ ID NO: 33, and a VHCDR3 of SEQ ID NO: 34; c) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 35, a VLCDR2 of SEQ ID NO: 36, and a VLCDR3 of SEQ ID NO: 37, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 38, a VHCDR2 of SEQ ID NO: 39, and a VHCDR3 of SEQ ID NO: 40; d) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 41, a VLCDR2 of SEQ ID NO: 42, and a VLCDR3 of SEQ ID NO: 43, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 44, a VHCDR2 of SEQ ID NO: 45, and a VHCDR3 of SEQ ID NO: 46, or e) a light chain variable domain comprising a VLCDR1 of SEQ ID NO: 47, a VLCDR2 of SEQ ID NO: 48, and a VLCDR3 of SEQ ID NO: 49, and a heavy chain variable domain comprising a VHCDR1 of SEQ ID NO: 50, a VHCDR2 of SEQ ID NO: 51, and a VHCDR3 of SEQ ID NO:

52. An anti-SIRPg antibody or an antigen-binding fragment thereof comprising:

2. 2. The antibody or antigen-binding fragment thereof of claim 1, which specifically binds to a polypeptide consisting of SEQ ID NO: 1 or 2.

3. An antibody or antigen-binding fragment thereof according to claim 1 or 2, which inhibits the binding of human CD47 to human SIRPg.

4. An antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, which does not inhibit the binding of human SIRPa to human CD47, and preferably does not bind to human SIRPa.

5. 5. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, which inhibits IFNg secretion, in particular by T cells, more preferably chronically activated T cells, compared to a negative control in the absence of the antibody, in particular where the inhibition of IFNg secretion is more than 20%, preferably more than 30%, more preferably more than 40% compared to a negative control, in particular where the IFNg secretion is measured by determining the level of IFNg secretion by T cells, preferably measured by an immunoassay.

6. 6. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the antibody is a humanized monoclonal antibody, in particular comprising a human IgG4 heavy chain constant region, preferably comprising SEQ ID NO: 103 and / or a human Igκ light chain constant region, or consisting only of SEQ ID NO: 103 and / or a human Igκ light chain constant region, preferably comprising or consisting only of SEQ ID NO:

104.

7. - a light chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 3 and a heavy chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 4; - a light chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO:5 and a heavy chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO:6; - a light chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 7 and a heavy chain variable domain comprising or consisting of the amino acid sequence consisting of SEQ ID NO: 8; - a light chain variable domain comprising or consisting of the amino acid sequence of SEQ ID NO: 9 and a heavy chain variable domain comprising or consisting of the amino acid sequence of SEQ ID NO: 10; or - a light chain variable domain comprising or consisting exclusively of the amino acid sequence of SEQ ID NO: 11 and a heavy chain variable domain comprising or consisting exclusively of the amino acid sequence of SEQ ID NO: 12 The anti-SIRPg antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, comprising:

8. 8. An isolated nucleic acid molecule or a combination of isolated nucleic acid molecules encoding an antibody or antigen-binding fragment thereof according to any one of claims 1 to 7.

9. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof described in any one of claims 1 to 7, or an isolated nucleic acid molecule described in claim 8, or a combination of said isolated nucleic acid molecules, and a pharmaceutical vehicle.

10. An antibody or antigen-binding fragment thereof described in any one of claims 1 to 7, an isolated nucleic acid molecule or a combination of isolated nucleic acid molecules described in claim 8, or a pharmaceutical composition described in claim 9, for use as a medicament.

11. An antibody or antigen-binding fragment thereof described in any one of claims 1 to 7, an isolated nucleic acid molecule or a combination of isolated nucleic acid molecules described in claim 8, or a pharmaceutical composition described in claim 9, for use as described in claim 10 in the prevention and treatment of diseases in which T cells have a detrimental effect, in particular diseases in which T cell proliferation and / or activation and / or migration and / or tissue infiltration by T cells has a detrimental effect.

12. The antibody or antigen-binding fragment thereof described in any one of claims 1 to 7, the isolated nucleic acid molecule or the combination of isolated nucleic acid molecules described in claim 8, or the pharmaceutical composition described in claim 9, for use as described in claim 11, wherein the disease is selected from the group consisting of autoimmune diseases, inflammatory diseases, immunometabolic diseases, cardiovascular diseases caused by systemic inflammation, transplant failure or rejection.

13. An antibody or antigen-binding fragment thereof described in any one of claims 1 to 7, an isolated nucleic acid molecule or a combination of isolated nucleic acid molecules described in claim 8, or a pharmaceutical composition described in claim 9, for use as described in claim 12, wherein the disease is graft-versus-host disease.

14. The antibody or antigen-binding fragment thereof described in any one of claims 1 to 7, the isolated nucleic acid molecule or the combination of isolated nucleic acid molecules described in claim 8, or the pharmaceutical composition described in claim 9, for use as described in claim 12, wherein the inflammatory disease is a chronic inflammatory disease such as inflammatory bowel disease including Crohn's disease or ulcer disease, or a chronic neuroinflammatory disease.

15. - an antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, an isolated nucleic acid molecule or a combination of isolated nucleic acid molecules according to claim 8, or a pharmaceutical composition according to claim 9; and - a second therapeutic agent selected from the group consisting of immunotherapeutic agents, immunosuppressants, antibiotics, probiotics and mixtures thereof, particularly for simultaneous, separate or sequential use as a medicine Combination products.

Citation Information

Patent Citations

  • NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

    WO2017178653A2

  • Anti-sirpg compounds

    WO2020039049A1